Chemistry and small-molecule patents

What can be protected

• New compoundsIndividual molecules and families of related compounds.
• Salts, crystal forms and formulationsForms and compositions that improve stability, solubility or delivery.
• Methods of treatment and dosingNew uses, patient groups and dosing regimens for active compounds.
• Synthesis and manufacturingNew routes, intermediates and processes.
• CombinationsCombinations of active ingredients and how they are given together.

Where patents in this field go wrong

1. Claims broader than the examples

   Claims to large families of compounds need enough examples and guidance to support their full scope. Courts have become stricter about this.

2. Obviousness over close analogs

   A compound that is structurally close to a known one may be rejected as obvious unless the application shows an unexpected advantage. Comparative data helps.

3. Timing the first filing

   The patent term generally runs 20 years from filing, and drug development takes years. Filing strategy should balance early protection against how much term remains at launch; patent term extension can restore part of the time lost to regulatory review.

4. Publishing results first

   Papers, posters and conference abstracts can bar patents outside the United States if they come before filing.

Building a small-molecule portfolio

1. Genus and lead

   First filings usually claim a genus around the lead series, with specific examples, so that close analogs are covered.

2. Methods of treatment

   Claims to treating particular diseases with the compounds add protection tied to the clinical program.

3. Follow-on filings

   As development continues, new salts, crystal forms, formulations and dosing regimens can support later patents.

4. Regulatory exclusivity

   For approved drugs, patents work alongside FDA exclusivities and patent term extension, which can restore part of the term used up during clinical trials.

How I work

I read the chemistry and the data, then help decide what to claim first (the compound, the form, the formulation or the use) and how to build protection in layers over the life of a program. See how I work.

Representative experience

Matters are described in general terms to protect client confidentiality.

• Patent prosecution in medicinal chemistry: small molecules, drug discovery and formulations
• Advised a biotechnology startup in licensing negotiations with a global life sciences and diagnostics company

Questions

Can we patent a new salt or crystal form of a known compound?

Often, if the form is new and not obvious, which is usually shown with data on unexpected properties such as stability or solubility. These patents are valuable but frequently challenged.

Can a method of treatment be patented?

In the United States, yes. Many other countries exclude methods of medical treatment but allow claims in other formats, such as a compound for use in treating a disease.

When should we file relative to preclinical work?

Before any public disclosure. Beyond that, the timing balances early protection against preserving term; a provisional application can secure a date while data develops.

What is patent term extension?

For a drug that needs FDA approval, U.S. law allows one patent to be extended to make up for part of the time spent in clinical trials and regulatory review. The extension is capped at five years, and at 14 years of remaining term after approval.

Do we need foreign patents before clinical trials?

Usually, if you will seek approval or partners outside the United States. Foreign rights depend on filing within deadlines set by your first application, typically through an international (PCT) application filed within 12 months.

Can we publish structure-activity data after filing?

Publishing no longer affects the application already on file, but the data becomes prior art against later filings on related compounds. Plan follow-on applications on close analogs before releasing broad structure-activity data.